Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion type Assertion NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_head.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion description "[Given that GTA has been chronically administered safely to infants with Canavan disease, a leukodystrophy due to ASPA mutation, GTA-mediated acetate supplementation may provide a novel, safe chemotherapeutic adjuvant to reduce the growth of glioma tumors, most notably the more rapidly proliferating, glycolytic and hypoacetylated mesenchymal glioma tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion evidence source_evidence_literature NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion SIO_000772 23996800 NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion wasDerivedFrom befree-20150227 NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion wasGeneratedBy ECO_0000203 NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.